{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:57:17Z","timestamp":1790236637119,"version":"4.1.0"},"reference-count":54,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,14]]},"DOI":"10.14797\/mdcvj.1070","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T08:56:20Z","timestamp":1647248180000},"page":"27-35","source":"Crossref","is-referenced-by-count":74,"title":["Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication"],"prefix":"10.14797","volume":"18","author":[{"given":"Kelty R.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"3-4","key":"key20220314085618_B1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/13506129.2010.526812","article-title":"Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis","volume":"17","year":"2010","journal-title":"Amyloid"},{"issue":"4","key":"key20220314085618_B2","first-page":"217","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","year":"2020","journal-title":"Amyhoid"},{"issue":"6","key":"key20220314085618_B3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"key20220314085618_B4","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2009-04-202879","article-title":"How I treat amyloidosis","volume":"114","year":"2009","journal-title":"Blood"},{"issue":"13","key":"key20220314085618_B5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"issue":"10","key":"key20220314085618_B6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"key20220314085618_B7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-020-00385-0","article-title":"Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities","volume":"10","year":"2020","journal-title":"Blood Cancer J"},{"issue":"15","key":"key20220314085618_B8","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"key20220314085618_B9","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-019-0400-5","article-title":"Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis","volume":"33","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"key20220314085618_B10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","article-title":"Prognostic restaging after treatment initiation in patients with AL amyloidosis","volume":"5","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"key20220314085618_B11","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","year":"2004","journal-title":"Blood"},{"issue":"2","key":"key20220314085618_B12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"key20220314085618_B13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"key20220314085618_B14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"issue":"24","key":"key20220314085618_B15","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","year":"2010","journal-title":"Blood"},{"key":"key20220314085618_B16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.leukres.2015.11.013","article-title":"Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis","volume":"41","year":"2016","journal-title":"Leuk Res"},{"issue":"4","key":"key20220314085618_B17","first-page":"245","article-title":"Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis","volume":"24","year":"2017","journal-title":"Amyloid"},{"issue":"4","key":"key20220314085618_B18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.14908","article-title":"Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis","volume":"179","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"key20220314085618_B19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3324\/haematol.2016.147041","article-title":"Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type","volume":"101","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"key20220314085618_B20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","year":"2017","journal-title":"Blood"},{"issue":"5","key":"key20220314085618_B21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","year":"2017","journal-title":"Blood"},{"issue":"12","key":"key20220314085618_B22","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00277-018-3460-0","article-title":"Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels","volume":"97","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"key20220314085618_B23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/leu.2017.286","article-title":"Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains","volume":"32","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"key20220314085618_B24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","article-title":"Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis","volume":"128","year":"2016","journal-title":"Blood"},{"issue":"10","key":"key20220314085618_B25","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/ajh.25576","article-title":"Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis","volume":"94","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"key20220314085618_B26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4065\/83.3.297","article-title":"Serum uric acid: novel prognostic factor in primary systemic amyloidosis","volume":"83","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"key20220314085618_B27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12185-019-02692-0","article-title":"Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis","volume":"110","year":"2019","journal-title":"Int J Hematol"},{"issue":"14","key":"key20220314085618_B28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","year":"2018","journal-title":"Blood"},{"issue":"3","key":"key20220314085618_B29","first-page":"218","article-title":"The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients","volume":"84","year":"1999","journal-title":"Haematologica"},{"issue":"3","key":"key20220314085618_B30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bjh.12269","article-title":"The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis","volume":"161","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"key20220314085618_B31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2018.1443439","article-title":"Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome","volume":"25","year":"2018","journal-title":"Amyloid"},{"issue":"3","key":"key20220314085618_B32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cam4.3683","article-title":"AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival","volume":"10","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"key20220314085618_B33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jjco\/hyy202","article-title":"Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma","volume":"49","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"key20220314085618_B34","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"key20220314085618_B35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","year":"2016","journal-title":"Blood"},{"issue":"3","key":"key20220314085618_B36","first-page":"455","article-title":"Prognostic significance of Holter monitor findings in patients with light chain amyloidosis","volume":"94","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"key20220314085618_B37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00380-019-01513-y","article-title":"Assessment of prognosis in immunoglobulin light chain amyloidosis patients with severe heart failure: a predictive value of right ventricular function","volume":"35","year":"2020","journal-title":"Heart Vessels"},{"issue":"12","key":"key20220314085618_B38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","article-title":"Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers","volume":"60","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20220314085618_B39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.echo.2017.08.017","article-title":"Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation","volume":"31","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"key20220314085618_B40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12872-021-01856-3","article-title":"Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters","volume":"21","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"key20220314085618_B41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ehjci\/jew100","article-title":"Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study","volume":"17","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"key20220314085618_B42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12968-019-0564-1","article-title":"Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis","volume":"21","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"key20220314085618_B43","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/jmri.27200","article-title":"Prognostic value of right ventricular dysfunction in patients with AL amyloidosis: comparison of different techniques by cardiac magnetic resonance","volume":"52","year":"2020","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"key20220314085618_B44","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure","volume":"9","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"key20220314085618_B45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00392-016-1058-x","article-title":"Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis","volume":"106","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"key20220314085618_B46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.leukres.2017.06.008","article-title":"Prognostic significance of interventricular septal thickness in patients with AL amyloidosis","volume":"60","year":"2017","journal-title":"Leuk Res"},{"issue":"1","key":"key20220314085618_B47","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/s41598-019-44245-9","article-title":"Associations of electrocardiographic parameters with left ventricular longitudinal strain and prognosis in cardiac light chain amyloidosis","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"key20220314085618_B48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jelectrocard.2020.02.001","article-title":"Prognostic significance of the frontal QRS-T angle in patients with AL cardiac amyloidosis","volume":"59","year":"2020","journal-title":"J Electrocardiol"},{"issue":"10","key":"key20220314085618_B49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/clc.23426","article-title":"Electrocardiographic parameters and prognosis of renal light chain amyloidosis","volume":"43","year":"2020","journal-title":"Clin Cardiol"},{"issue":"8","key":"key20220314085618_B50","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/CIRCRESAHA.119.314862","article-title":"Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis","volume":"125","year":"2019","journal-title":"Circ Res"},{"issue":"4","key":"key20220314085618_B51","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00392-020-01698-7","article-title":"Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis","volume":"110","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"key20220314085618_B52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/10428194.2020.1849675","article-title":"Posttreatment dFLC less than 10 mg\/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib","volume":"62","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"key20220314085618_B53","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41409-020-01136-2","article-title":"Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis","volume":"56","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"key20220314085618_B54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13506129.2019.1666709","article-title":"Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis","volume":"27","year":"2020","journal-title":"Amyloid"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T08:56:56Z","timestamp":1647248216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1070\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,14]]}},"alternative-id":["10.14797\/mdcvj.1070"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1070","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}